Meyka AI API is live for developers.Start building.
Advertisement
Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. (CERE) Stock Overview

Explore Cerevel Therapeutics Holdings, Inc.’s financial performance, market position, analyst ratings, and future outlook.

CERE●NASDAQ
HealthcareBiotechnology
$44.96
$0.33(0.74%)
U.S. Market opens in 56h 3m
Advertisement

Cerevel Therapeutics Holdings, Inc. (CERE)

Meyka AI Score

Z

Key Financials

Market Cap8.2B
P/E Ratio-16.83
EPS (TTM)$-2.73
ROE-0.72%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$58.57

CERE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Cerevel Therapeutics Holdings, Inc. (CERE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $58.57.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -16.83 and a market capitalization of 8.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
0.74%
3-Month Change
10.63%
6-Month Change
9.66%
Year-to-Date (YTD) Change
6.52%
1-Year Change
87.88%
3-Year Change
45.17%
5-Year Change
277.82%
All-Time (Max) Change
277.82%

Contact Information

https://www.cerevel.com
844 304 2048
222 Jacobs Street, Cambridge, MA, 02141

Company Facts

3,550 Employees
IPO DateJul 30, 2020
CountryUS

Frequently Asked Questions